Skip to main content
SpringerLink
Log in

Ulcerative colitis

Steroid-refractory ulcerative colitis—ciclosporin or infliximab?

  • News & Views
  • Published:

From Nature Reviews Gastroenterology & Hepatology

View current issue Sign up to alerts

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Ciclosporin and infliximab are used as rescue therapies for the treatment of severe steroid-refractory ulcerative colitis. Now, an open-label, head-to-head randomized controlled trial has demonstrated that these drugs are well-tolerated and have equivalent efficacy in inducing short-term clinical response, mucosal healing and decreasing colectomy rates at 3 months.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Truelove, S. C. & Jewell, D. P. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1, 1067–1070 (1974).

    Article  CAS  Google Scholar 

  2. Laharie, D. et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet http://dx.doi.org/10.1016/S0140-6736(12)61084-8.

  3. Lichtiger, S. et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N. Engl. J. Med. 330, 1841–1845 (1994).

    Article  CAS  Google Scholar 

  4. Actis, G. C. et al. Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study. BMC Gastroenterol. 7, 13 (2007).

    Article  Google Scholar 

  5. Moskovitz, D. N. et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin. Gastroenterol. Hepatol. 4, 760–765 (2006).

    Article  CAS  Google Scholar 

  6. Sands, B. E. et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm. Bowel Dis. 7, 83–88 (2001).

    Article  CAS  Google Scholar 

  7. Probert, C. S. et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 52, 998–1002 (2003).

    Article  CAS  Google Scholar 

  8. Jarnerot, G. et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128, 1805–1811 (2005).

    Article  Google Scholar 

  9. Rutgeerts, P. et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353, 2462–2476 (2005).

    Article  CAS  Google Scholar 

  10. Rowe, F. A. et al. Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis. Am. J. Gastroenterol. 95, 2000–2008 (2000).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Inflammatory Bowel Disease Center, Cedars–Sinai Medical Center, 8730 Alden Drive, Thalians Suite 2E, Los Angeles, 90048, CA, USA

    Manreet Kaur & Stephen R. Targan

Authors
  1. Manreet Kaur
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen R. Targan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manreet Kaur.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaur, M., Targan, S. Steroid-refractory ulcerative colitis—ciclosporin or infliximab?. Nat Rev Gastroenterol Hepatol 10, 8–9 (2013). https://doi.org/10.1038/nrgastro.2012.235

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2012.235

  • Springer Nature Limited

Search

Navigation